PITTSTON, ME--(Marketwire - Feb 5, 2013) - YaFarm Technologies, Inc. (
YaFarm Technologies CEO Brian Hermenze stated, "Since the 2012 Nobel Prize in Physiology or Medicine was awarded jointly to John B. Gurdon and Shinya Yamanaka for their work in stem cell research, we are very excited about the synergies this acquisition will bring to the Company. The ISCI has been providing point-of-care therapies to patients for over a year and operates at an internationally recognized medical facility accredited by both the Joint Commission and Accreditation Canada International. With a seasoned and successful management team in place, we believe we are creating an organization that has the capabilities to understand and support the many facets of the stem cell industry. We believe that there will be significant growth opportunities in stem cell research and treatment in the near future, and it is our intent to capitalize on them."
Juan Castillo, MD, founder of the ISCI said, "Physicians from around the world have shown that cells may have a tremendous impact on such chronic and debilitating diseases as diabetes, Parkinson's disease and Chronic Obstructive Pulmonary Disease (COPD)." Dr. Castillo continued, "The ISCI provides quality patient care and a uniquely integrated medical community. Our patients, physicians and researchers work together to provide access to innovative, point-of-care, cell-based therapies, while evidencing the regenerative capabilities of cell medicine, and delivering on the promise of adult stem cell therapies."
In addition, the Company has received final approval from the Financial Industry Regulatory Authority (FINRA) for a 4 for 1 forward stock split. To receive the dividend the investor must be a registered shareholder of record on the Company's books on or before the record date of January 18, 2013. Shareholders who were not registered as of this date will not receive the dividend. Shares of YaFarm began trading ex-dividend on January 22, 2013.
YaFarm Technologies currently has 49,857,368 shares issued and outstanding. Of the issued and outstanding, the current public float is 17,908,975 and 31,948,393 shares are restricted.
About Integrative Stem Cell Institute (ISCI)
The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effectively track long term outcomes and assure patient safety.
More information on The Integrative Stem Cell Institute is available on the company's website at www.iscelli.com.
SAFE HARBOR STATEMENT
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition, adequate financing, and other material risks. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance, or achievements to be materially different from the statements made herein.
- Investment & Company Information
- stem cell research
- regenerative medicine
Atlanta Capital Partners, LLC